Literature DB >> 10581440

Stable recombinant expression of the anti HIV-1 monoclonal antibody 2F5 after IgG3/IgG1 subclass switch in CHO cells.

R Kunert1, W Steinfellner, M Purtscher, A Assadian, H Katinger.   

Abstract

The human monoclonal antibody (humAb) 2F5 is a potent candidate for immunotherapy of HIV-1. The xenohybridoma derived humAb 2F5 is of IgG3 kappa isotype. Generally, IgG1 isotype has a longer half-life (beta-clearance) in humans than IgG3. Therefore the isotype was switched to an IgG1 by ligation of the 2F5 heavy chain variable region to an IgG1 constant region and expressed as IgG1 kappa in CHO cells. CHO clones have been established, which stably express humAb 2F5 at high levels. The specificity, affinity and in vitro function of both isotypes were identical. Copyright 2000 John Wiley & Sons, Inc.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10581440     DOI： 10.1002/(sici)1097-0290(20000105)67:1<97::aid-bit11>3.0.co;2-2

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN： 0006-3592            Impact factor:   4.530


  21 in total

1.  Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes.

Authors:  Eve de Rosny; Russell Vassell; Shibo Jiang; Renate Kunert; Carol D Weiss
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

2.  Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection.

Authors:  Saurabh Mehandru; Brigitta Vcelar; Terri Wrin; Gabriela Stiegler; Beda Joos; Hiroshi Mohri; Daniel Boden; Justin Galovich; Klara Tenner-Racz; Paul Racz; Mary Carrington; Christos Petropoulos; Hermann Katinger; Martin Markowitz
Journal:  J Virol       Date:  2007-08-08       Impact factor: 5.103

3.  Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region.

Authors:  Elin S Gray; Maphuti C Madiga; Penny L Moore; Koleka Mlisana; Salim S Abdool Karim; James M Binley; George M Shaw; John R Mascola; Lynn Morris
Journal:  J Virol       Date:  2009-08-19       Impact factor: 5.103

4.  Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5).

Authors:  Beda Joos; Alexandra Trkola; Herbert Kuster; Leonardo Aceto; Marek Fischer; Gabriela Stiegler; Christine Armbruster; Brigitta Vcelar; Hermann Katinger; Huldrych F Günthard
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

5.  Production of anti TNF-α antibodies in eukaryotic cells using different combinations of vectors carrying heavy and light chains.

Authors:  Dmitriy Balabashin; Elena Kovalenko; Viktoria Toporova; Teimur Aliev; Anna Panina; Elena Svirshchevskaya; Dmitry Dolgikh; Mikhail Kirpichnikov
Journal:  Cytotechnology       Date:  2014-06-18       Impact factor: 2.058

6.  Serum-free transfection of CHO cells with chemically defined transfection systems and investigation of their potential for transient and stable transfection.

Authors:  Hannes Reisinger; Willibald Steinfellner; Hermann Katinger; Renate Kunert
Journal:  Cytotechnology       Date:  2009-09-17       Impact factor: 2.058

7.  Functional characterization of the recombinant HIV-neutralizing monoclonal antibody 2F5 produced in maize seeds.

Authors:  M Sabalza; L Madeira; C van Dolleweerd; J K Ma; T Capell; P Christou
Journal:  Plant Mol Biol       Date:  2012-09-11       Impact factor: 4.076

8.  Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques.

Authors:  C Moog; N Dereuddre-Bosquet; J-L Teillaud; M E Biedma; V Holl; G Van Ham; L Heyndrickx; A Van Dorsselaer; D Katinger; B Vcelar; S Zolla-Pazner; I Mangeot; C Kelly; R J Shattock; R Le Grand
Journal:  Mucosal Immunol       Date:  2013-04-17       Impact factor: 7.313

9.  Neutralizing IgG at the portal of infection mediates protection against vaginal simian/human immunodeficiency virus challenge.

Authors:  Katja Klein; Ronald S Veazey; Ranjit Warrier; Peter Hraber; Lara A Doyle-Meyers; Viviana Buffa; Hua-Xin Liao; Barton F Haynes; George M Shaw; Robin J Shattock
Journal:  J Virol       Date:  2013-08-21       Impact factor: 5.103

10.  The broadly neutralizing anti-human immunodeficiency virus type 1 4E10 monoclonal antibody is better adapted to membrane-bound epitope recognition and blocking than 2F5.

Authors:  Nerea Huarte; Maier Lorizate; Rubén Maeso; Renate Kunert; Rocio Arranz; José M Valpuesta; José L Nieva
Journal:  J Virol       Date:  2008-07-02       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.